Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 4/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599614 | 0.89 | CREBBP (0.54) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL597474 | 0.89 | ALDH1A1 (0.59) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL598451 | 0.88 | ALDH1A1 (0.58) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL599049 | 0.88 | ALDH1A1 (0.60) | ALDH1A1HPGDSMN1; SMN2KMT2AMAPT | |
| SCHEMBL598915 | 0.86 | SHMT2 (0.56) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL599153 | 0.85 | RAB9A (0.59) | ALDH1A1HPGDSMN1; SMN2KMT2AMAPT | |
| SCHEMBL598819 | 0.83 | ALDH1A1 (0.57) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL598268 | 0.81 | ALDH1A1 (0.48) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL599366 | 0.81 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL599133 | 0.80 | ALDH1A1 (0.54) | CNR2CNR1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | claimed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | HTR2C, HTR3A, HTR3C | P2RX7 242/4885CNR2 23/4885CNR1 26/4885 |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | P2RX7 242/4885CNR2 23/4885CNR1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.